Effects of calcitonin on knee osteoarthritis and quality of life
- 382 Downloads
There has been a recent interest in calcitonin as a potential treatment for osteoarthritis, based on its metabolic activities in both bone turnover and cartilage. The aim of this study was to evaluate the effects of nasal form calcitonin on knee osteoarthritis and quality of life in women who receive calcitonin treatment for postmenopausal osteoporosis. Two hundred and twenty postmenopausal women, aged between 55 and 65 years with knee pain and knee osteoarthritis, graded II–III by using Kellgren–Lawrence radiographic scoring system, were included. Western Ontario and McMaster Universities (WOMAC) osteoarthritis index, the quality of life questionnaire of the European Foundation for Osteoporosis (QALEFFO-41) and visual analog scale were used for the algofunctional assessments. Need of rescue analgesic was recorded. Pain (P < 0.001), stiffness (P < 0.05), functional capability (P < 0.05) and total score of WOMAC (P < 0.05) revealed statistically significant improvements after 3 months of the treatment and remained consistent throughout 1 year of the treatment period. Participants experienced significant reductions in WOMAC perceptions of pain (−53 %), joint stiffness (−44 %) and limitations in physical function (−49 %) at the end of 1 year of calcitonin treatment. Need of rescue analgesic intake was reported to have decreased approximately by 60 % at the end of the 1-year treatment period. QUALEFFO_41 scores improved: 37.6 (baseline), 30.9 (3 months), 28.0 (6 months) and 24.4 (1 year). In conclusion, nasal calcitonin treatment provided dual action on osteoporosis and osteoarthritis with significant improvements in quality of life and algofunctional results in knee osteoarthritis.
KeywordsOsteoporosis Osteoarthritis Calcitonin treatment Rescue analgesic
Conflict of interest
The authors declare that they have no conflict of interest.
- 12.El Hajjaji H, Williams JM, Devogelaer JP, Lenz ME, Thonar EJ, Manicourt DH (2004) Treatment with calcitonin prevents the net loss of collagen, hyaluronan and proteoglycan aggregates from cartilage in the early stages of canine experimental osteoarthritis. Osteoarthr Cartil 12:904–911PubMedCrossRefGoogle Scholar
- 17.Bingham CO, Buckland-Wright JC, Garnera P et al (2006) Risedronate decreases biomechanical markers of cartilage degradation but does not decrease symptoms or slow X-ray progression in patients with medial compartment osteoarthritis of the knee: results of 2 year multinational knee OA structural arthritis (KOSTAR) study. Arthritis Rheum 54:3494–3507PubMedCrossRefGoogle Scholar
- 18.Karsdal MA, Byrjalsen I, Bay-Jensen AC, Henriksen K, Riis BJ, Christiansen C (2010) Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis—the effect of sex, Kellgren–Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation. BMC Musculoskelet Disord 11:125PubMedCrossRefGoogle Scholar
- 20.Manicourt DH, Devogelaer JP, Azria M, Silverman S (2005) Rationale for the potential use of calcitonin in osteoarthritis. J Muskuloskelet Neuronal Interact 5:285–293Google Scholar
- 24.Azria M (1989) The calcitonins (physiology and pharmacology). Karger, BaselGoogle Scholar
- 27.Sondergaard BS, Olsen AK, Sumer EU, Quvist P, Bagger YZ, Tanko LB et al (2005) Calcitonin stimulates proteoglycan and collagen type I1 biosynthesis in articular cartilage ex vivo. Osteoarthr Cartil 13(Suppl A):142Google Scholar
- 31.Tanko LB, Bagger YZ, Alexandersen P, Devogelaer JP, Reginster JY, Chick R et al (2004) Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res 19:1531–1538PubMedCrossRefGoogle Scholar
- 34.Manicourt DH, Azria M, Mindeholm L, Devogelaer JP (2005) Efficacy of calcitonin therapy in patients with knee osteoarthritis: a clinical and biochemical preliminary study. Osteoarthr Cartil 13:88Google Scholar